Incyte’s Hodgkin Lymphoma Treatment Receives FDA Orphan Drug Designation

Industry News

The U.S. Food and Drug Administration (FDA) has granted INCB40093 Orphan Drug Designation (ODD) for the treatment of Hodgkin lymphoma (HL).  INCB4009 is a potent small molecule PI3Kδ inhibitor being developed by Incyte Inc., a biopharmaceutical company headquartered in Wilmington, DE.  PI3Kδ plays an essential role in promoting B-cell survival and excessive activation of PI3Kδ is associated with HL. HL is an uncommon lymphoma with a bimodal incidence curve.  Although HL has remained a largely curable disease, approximately 20% of patients will not be cured with currently available therapy and will require subsequent treatments.

 

Related Links:

http://www.streetinsider.com/Corporate+News/Incyte+%28INCY%29+Receives+Orphan+Drug+Designation+for+Treatment+of+Hodgkin+Lymphoma/10506476.html
http://www.google.com/patents/US8940752
http://investor.incyte.com/phoenix.zhtml?c=69764&p=irol-newsArticle&ID=2042128
http://www.bloodjournal.org/content/bloodjournal/119/8/1897.full.pdf?sso-checked=true

Subscribe to WXPress

Receive our newsletter and information on upcoming events.